Organon & Co. (NYSE:OGN – Get Free Report) and Basel Medical Group (NASDAQ:BMGL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Valuation & Earnings
This table compares Organon & Co. and Basel Medical Group”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organon & Co. | $6.22 billion | 0.27 | $187.00 million | $0.71 | 8.95 |
| Basel Medical Group | $8.90 million | 1.28 | -$9.50 million | N/A | N/A |
Analyst Ratings
This is a breakdown of current ratings and target prices for Organon & Co. and Basel Medical Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organon & Co. | 5 | 1 | 0 | 1 | 1.57 |
| Basel Medical Group | 1 | 0 | 0 | 0 | 1.00 |
Organon & Co. presently has a consensus price target of $8.50, suggesting a potential upside of 33.77%. Given Organon & Co.’s stronger consensus rating and higher possible upside, analysts clearly believe Organon & Co. is more favorable than Basel Medical Group.
Insider & Institutional Ownership
77.4% of Organon & Co. shares are held by institutional investors. 2.0% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Organon & Co. and Basel Medical Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organon & Co. | 3.01% | 122.01% | 6.74% |
| Basel Medical Group | N/A | N/A | N/A |
Risk and Volatility
Organon & Co. has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Basel Medical Group has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500.
Summary
Organon & Co. beats Basel Medical Group on 11 of the 12 factors compared between the two stocks.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
About Basel Medical Group
Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
